Clinical Trial Update: Prospective, Open-Label, Multicenter, International Study of Mifepristone for Symptomatic Treatment of Cushing's Syndrome Caused by Ectopic Adrenal Corticotrophin Hormone (ACTH) Secretion [Phase 2]

View source ↗

Summary

Phase 2 open-label trial of mifepristone for symptomatic treatment of Cushing's syndrome due to ectopic ACTH secretion; study terminated with results posted in …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cushing Syndrome

Drugs mentioned

• Mifepristone (mifepristone)

Snippet

Sponsor: HRA Pharma | Conditions: Cushing's Syndrome | Phase 2 | Status: TERMINATED | Results posted: 2013-10-14